Aaron Thomson's questions to bioAffinity Technologies (BIAF) leadership • Q4 2022
Question
Private investor Aaron Thomson inquired about the company's therapeutic research pipeline, specifically its work with siRNA, and requested an update on the European expansion strategy for CyPath Lung, including the timeline for CE marking.
Answer
President and CEO Maria Zannes explained that the company's therapeutic research, while still in early stages, involves using siRNA to kill cancer cells without harming normal cells, with animal studies planned. Regarding European expansion, Zannes stated the company is targeting the Netherlands first due to its receptiveness to new technology. She anticipates completing the more rigorous CE marking process in the next year and noted CyPath Lung could potentially be used as a primary screening test in the EU, given its high sensitivity and specificity.